VivoSeq
Infectious Disease

HPV Infection

2

Pipeline Programs↗

7

Active Trials↗

3

Companies Involved↗

HPV Infection is an early-stage landscape with 2 programs across 3 companies. The most active players are Eli Lilly, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., MGB Pharma.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2S

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

0 programs

PreclinicalM

MGB Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Recruiting4 · 31%
Not yet recruiting2 · 15%
Withdrawn1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection
Recruiting·PPeking University People's Hospital·N/A·NCT06467942·240 enrolled
HUC-MSC for Treatment of High-risk HPV Infection
Recruiting·SShanghai East Hospital·Phase 1/2·NCT06610773·60 enrolled
Double-Blind Randomized Phase II Clinical Trial Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ <CIN2
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06210854·48 enrolled
Treatment of Infections of the Cervix Uteri With High- and Low-risk Variants of the Human Papillomavirus Using Non-invasive Physical Plasma
Recruiting·UUniversity Hospital Tuebingen·N/A·NCT06291311·50 enrolled
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
Active, not recruiting·WWeill Medical College of Cornell University·Phase 3·NCT04255849·700 enrolled
Tolerance and Effectiveness of C14 on HPV Infection
Not yet recruiting·MMGB Pharma·Phase 1/2·NCT06672653·66 enrolled
An Interventional Study Evaluating the Effect of Epigallocatechin Gallate (EGCG), Folic Acid (FA), Vitamin B12 (B12) and Hyaluronic Acid (HA) in Affecting the DNA Integration of Human Papilloma Virus (HPV) in Women With Persistent Infection
Not yet recruiting·IIRCCS San Raffaele·Preclinical·NCT07697196·42 enrolled
Interferon Alpha Therapy for Cervical CINI and HPV Infection
Completed·MMongolian National University of Medical Sciences·Phase 1·NCT06137950·60 enrolled
Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia
Completed·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 2·NCT02304770·73 enrolled
Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection
Completed·LLiaquat University of Medical & Health Sciences·N/A·NCT06752083·289 enrolled
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Completed·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 2·NCT06439433·119 enrolled
Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases
Completed·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT06302725·278 enrolled
Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants
Withdrawn·RRutgers, The State University of New Jersey·Phase 2·NCT02382419

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)